Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer

Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.